Table 1.

Characteristics of patients with RAPID3 or PsAID12 data (n = 347)*.

CharacteristicsValues
Age, yrs, mean (SD)51.7 (14.0)
Sex
  Female, n (%)186 (53.6)
Race, n (%)
  White300 (86.5)
  Black6 (1.7)
  Native American2 (0.6)
  Asian12 (3.5)
  Other13 (3.8)
  Unknown7 (2.0)
BMI, mean (SD)29.2 (6.7)
Ethnicity
  Hispanic, n (%)7 (2.0)
Center, n (%)
  Cleveland Clinic91 (26.2)
  New York University47 (13.5)
  University of Utah148 (42.7)
  University of Pennsylvania61 (17.6)
Current therapies, n (%)
  Methotrexate114 (32.9)
  Leflunomide17 (4.9)
  Sulfasalazine19 (5.5)
  Apremilast14 (4.0)
  Adalimumab61 (17.6)
  Etanercept67 (19.3)
  Certolizumab3 (0.9)
  Golimumab9 (2.6)
  Infliximab20 (5.8)
  Ustekinumab16 (4.6)
  Secukinumab2 (0.6)
  HCQ6 (1.7)
  Any nbDMARD or bDMARD231 (66.6)
Joint counts, mean (SD)^
  66 swollen2.2 (3.8)
  68 tender4.3 (7.2)
  76 swollen4.5 (11.2)
  78 tender7.3 (12.5)
PGA, mean (SD)
  Overall3.4 (2.2)
  Arthritis3.0 (2.2)
  Skin2.0 (2.2)
PtGA**, mean (SD)3.7 (2.7)
Pain assessment, mean (SD)4.0 (2.8)
HAQ score, mean (SD)1.6 (1.7)
RAPID3, mean (SD)8.6 (6.1)
PsAID9*, mean (SD)3.4 (2.4)
PsAID12*, mean (SD)3.2 (2.4)
  • * PsAID was completed by 208 patients; RAPID3 was completed by 341 patients.

  • ** The global assessments use the 0–10 range and were taken from the RAPID3.

  • Some patients were receiving concomitant therapy; percentages do not sum up to 100.

  • ^ One center collected only the 76/78 joint count. BMI: body mass index; HAQ: Health Assessment Questionnaire; nbDMARD: nonbiologic disease-modifying antirheumatic drug; bDMARD: biologic DMARD; RAPID3: Routine Assessment of Patient Index Data, range 0–30; HCQ: hydroxychloroquine; PsAID: Psoriatic Arthritis Impact of Disease questionnaire; PGA: physician global assessments; PtGA: patient global assessments.